Search research articles
Contact Us
Filters
Showing results (151-160 of 161) with videos related to
Page
of 17
Sort By:
Allergy
|
July 1, 2022
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
Sarah Diver, Koirobi Haldar, Pamela Jane McDowell, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.
The European Respiratory Journal
|
September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
John Busby, John G Matthews, Rekha Chaudhuri, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
P Jane McDowell, John Busby, Catherine E Hanratty, et al.
Science Translational Medicine
|
August 21, 2015
TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma
David F Choy, Kevin M Hart, Lee A Borthwick, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex
Matthew C Eastwood, John Busby, David J Jackson, et al.
The Lancet. Respiratory Medicine
|
September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Liam G Heaney, John Busby, Catherine E Hanratty, et al.
The Journal of Allergy and Clinical Immunology
|
June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control
Xue Zeng, Jing Qing, Chi-Ming Li, et al.
Journal of Medicinal Chemistry
|
July 12, 2021
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Giuseppe Campiani, Caterina Cavella, Jeremy D Osko, et al.
Thorax
|
July 25, 2015
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 161) with videos related to
Sort By:
Page
of 17
Allergy
|
July 1, 2022
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
Sarah Diver, Koirobi Haldar, Pamela Jane McDowell, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.
The European Respiratory Journal
|
September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
John Busby, John G Matthews, Rekha Chaudhuri, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
P Jane McDowell, John Busby, Catherine E Hanratty, et al.
Science Translational Medicine
|
August 21, 2015
TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma
David F Choy, Kevin M Hart, Lee A Borthwick, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex
Matthew C Eastwood, John Busby, David J Jackson, et al.
The Lancet. Respiratory Medicine
|
September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Liam G Heaney, John Busby, Catherine E Hanratty, et al.
The Journal of Allergy and Clinical Immunology
|
June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control
Xue Zeng, Jing Qing, Chi-Ming Li, et al.
Journal of Medicinal Chemistry
|
July 12, 2021
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Giuseppe Campiani, Caterina Cavella, Jeremy D Osko, et al.
Thorax
|
July 25, 2015
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, et al.
Page
of 17